Objectives To propose an integrative clinical–biological hypothesis whereby progressive functional deterioration in advanced cancer constitutes the final common pathway of systemic decline, driven by persistent inflammation, catabolic metabolic dysregulation and impairment of stress–response systems. Methods Narrative synthesis drawing on observations from established prognostic models (eg, Palliative Prognostic Score, Palliative Prognostic Index) and translational evidence concerning systemic inflammation, cachexia, metabolic mediators and stress-system dysregulation in advanced malignancy. Results Performance status measures—Eastern Cooperative Oncology Group (ECOG) Performance Status, Karnofsky Performance Status and Palliative Performance Scale—consistently demonstrate independent and often dominant prognostic value across diverse clinical settings and modelling strategies. Converging clinical and biological observations suggest that progressive functional decline reflects cumulative erosion of physiological reserve and adaptive capacity, mediated by persistent low-grade systemic inflammation, a predominantly catabolic metabolic state and chronic dysregulation of stress–response pathways. This interplay leads to diminished homeostatic flexibility, resulting in disproportionate decompensation to minor intercurrent stressors and acceleration of terminal decline. Conclusions Functional status may represent more than a descriptive prognostic indicator; it could embody the clinical manifestation of progressive loss of systemic resilience. The proposed resilience–threshold model frames a non-linear trajectory, leading to irreversible functional collapse once a critical threshold of adaptive reserve is exceeded. This conceptual framework has the potential to refine prognostic interpretation, inform proportionate therapeutic decisions and encourage prospective validation in palliative oncology.
Juan Santos Suárez (Sat,) studied this question.